Melanoma Clinical Trials

Showing 1241-1260 of 1,292 trials

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma

NCT01455103

The purpose of this study is to evaluate pharmacodynamic changes of BMS-936559 treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with unresectable Stage III or IV Melanoma.

Stage III or IV Melanoma

Bristol-Myers SquibbStarted Nov 2011

WITHDRAWNPhase 1

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

NCT00803374

The purpose of this study is to determine if BMS-663513 administered in combination with ipilimumab to patients with advanced malignant melanoma is safe and tolerable

Melanoma

Bristol-Myers SquibbStarted Nov 2010

Los Angeles, California, United States • New Haven, Connecticut, United States • Tampa, Florida, United States +4 more locations

COMPLETEDPhase 3

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

NCT00518895

This study is being performed to prospectively determine whether dacarbazine plus Genasense is significantly better than dacarbazine plus placebo in chemotherapy-naive patients with advanced melanoma and low baseline LDH (LDH less than or equal to 0.8 times the upper limit of normal). LDH is a biomarker strongly associated with improved outcomes in a recent trial of dacarbazine plus Genasense.

Melanoma

Genta Incorporated300 participantsStarted Jul 2007

Mobile, Alabama, United States • Encinitas, California, United States • Santa Rosa, California, United States +74 more locations

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Related Searches

Pharmacokinetics of G3139 in Subjects With Advanced Melanoma, Including Those With Normal Hepatic Function and Those With Moderate Hepatic Impairment

CP-461 in the Treatment of Patients With Advanced Melanoma

Study of XL281 in Adults With Solid Tumors

Photodynamic Therapy in Treating Patients With Skin Cancer or Solid Tumors Metastatic to the Skin

Post-Operative Drainage Following Lymph Node Dissection

Dose Escalation and Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma

Phase II Trial of Allovectin-7® for Metastatic Melanoma

Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

TNFerade™ Biologic Plus Radiation for Metastatic Melanoma

High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma

Differential Risks for Melanoma: p16 and DNA Repair

Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy

A Phase I/II Study of Sunitinib and Dacarbazine

Role of SLURP-1 in Melanoma and Melanoma Stem Cells

Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma

A Survey Study to See if Patients Diagnosed With Parkinson's Disease Have Higher Incidence of Melanoma